Search Results
You are looking at 1 - 4 of 4 items for
- Author: C Renner x
- Refine by access: All content x
Search for other papers by M Schmidt in
Google Scholar
PubMed
Search for other papers by C Renner in
Google Scholar
PubMed
Search for other papers by G Loffler in
Google Scholar
PubMed
In fibroblasts derived from human adipose tissue, aromatase induction is observed after exposure to 1 microM cortisol in the presence of serum or platelet-derived growth factor (PDGF). Progesterone suppresses this induction in a dose-dependent manner, 10 microM resulting in complete inhibition. A reduced cortisol concentration (0.1 microM) concomitantly reduces the progesterone concentration required for effective inhibition (10-100 nM). This effect of progesterone is specific, as neither the release of cellular enzymes nor aromatase induction by dibutyryl-cAMP, which acts independently from cortisol, are affected. However, the inhibitory effect of progesterone requires its presence throughout the induction period. Kinetic studies in intact cells reveal a reduced number of aromatase active sites upon progesterone treatment, whereas progesterone at near-physiological concentration (100 nM) does not inhibit aromatase activity in isolated microsomes. Semi-quantitative reverse transcriptase PCR analysis shows reduced amounts of aromatase mRNA in progesterone-treated cells, indicating specific inhibition of the glucocorticoid-dependent pathway of aromatase induction. The inhibitory effect of progesterone is not blocked by the anti-progestin ZK114043, excluding action via progesterone receptors and indicating competition for the glucocorticoid receptor. Progesterone must be considered a potential physiological inhibitor of glucocorticoid-dependent aromatase induction in adipose tissue. It is proposed that it is a suppressor of aromatase induction in adipose tissue in premenopausal women.
Search for other papers by J Manolopoulou in
Google Scholar
PubMed
Medizinische Klinik Innenstadt, Institute of Molecular Animal Breeding and Biotechnology, Division of Endocrinology, Institute for Molecular Medicine and Cell Research, Laboratory of Mouse Genetics, Ludwig-Maximilians University, Ziemssenstr. 1, 80336 Munich, Germany
Search for other papers by M Bielohuby in
Google Scholar
PubMed
Search for other papers by S J Caton in
Google Scholar
PubMed
Search for other papers by C E Gomez-Sanchez in
Google Scholar
PubMed
Search for other papers by I Renner-Mueller in
Google Scholar
PubMed
Search for other papers by E Wolf in
Google Scholar
PubMed
Search for other papers by U D Lichtenauer in
Google Scholar
PubMed
Search for other papers by F Beuschlein in
Google Scholar
PubMed
Medizinische Klinik Innenstadt, Institute of Molecular Animal Breeding and Biotechnology, Division of Endocrinology, Institute for Molecular Medicine and Cell Research, Laboratory of Mouse Genetics, Ludwig-Maximilians University, Ziemssenstr. 1, 80336 Munich, Germany
Search for other papers by A Hoeflich in
Google Scholar
PubMed
Search for other papers by M Bidlingmaier in
Google Scholar
PubMed
Data on the involvement of aldosterone in the regulation of the renin–angiotensin–aldosterone system (RAAS) in rodents are still scarce, partly due to the high sample volumes needed by commercially available assays and to the very low aldosterone concentrations present. We have developed a highly sensitive and non-isotopic immunoassay, requiring a volume of only 50 μl serum for a duplicate measurement, employing a highly specific monoclonal antibody against aldosterone. The assay was validated in human and mouse samples and exhibited a linear working range from 10 to 1000 pg/ml. Values obtained after a chromatographic purification step correlated significantly to the dichloromethane extraction ordinarily used. Basal aldosterone values were measured in 75 mouse hybrids and found within the linear range (173±21 pg/ml), with no significant difference between males and females. Additionally, we show an increase in serum aldosterone in mice from 3 to 11 weeks of age. Mice of the same genetic background were treated with dexamethasone intraperitoneally (n=7), resulting in significantly decreased concentrations (35±3 vs 114±33 pg/ml in controls; P<0.001). In contrast, adrenocorticotropic hormone resulted in significantly increased serum aldosterone (603±119 pg/ml; n=7; P<0.001), as did the physiological stimulation of the RAAS by a high K+/low Na+ diet (1369±703 vs 172±36 pg/ml). In conclusion, we have developed and validated an extremely sensitive assay for determination of aldosterone concentrations from very small serum samples, which could be especially useful in pharmacological intervention studies in rodent models.
Search for other papers by C Perez Castro in
Google Scholar
PubMed
Search for other papers by A Carbia Nagashima in
Google Scholar
PubMed
Search for other papers by M Paez Pereda in
Google Scholar
PubMed
Search for other papers by V Goldberg in
Google Scholar
PubMed
Search for other papers by A Chervin in
Google Scholar
PubMed
Search for other papers by G Carrizo in
Google Scholar
PubMed
Search for other papers by H Molina in
Google Scholar
PubMed
Search for other papers by U Renner in
Google Scholar
PubMed
Search for other papers by GK Stalla in
Google Scholar
PubMed
Search for other papers by E Arzt in
Google Scholar
PubMed
Two of the most potent cytokines regulating anterior pituitary cell function are leukemia inhibitory factor (LIF) and interleukin (IL)-6, which belong to the cytokine family using the common gp130 signal transducer. Recently, the expression and action of two other members of this family, IL-11 and ciliary neurotrophic factor (CNTF), on different cell lines has also been demonstrated. We studied the expression of the specific receptor subunits for CNTF in mammotropic, non-functioning and somatotropic tumors and the action of CNTF and IL-11 in the regulation of hormone secretion in these and normal pituitary cells. The mRNA for the alpha chain specific for the CNTF receptor was detected by Northern blot in tumors secreting prolactin (PRL) and GH and in non-functioning tumors. We found that both IL-11 and CNTF exerted a similar stimulatory effect on GH mRNA expression in somatotropic monolayer cell cultures from acromegalic tumors, but these cytokines had no significant influence on GH secretion. CNTF stimulates prolactin secretion in lactotropic monolayer cell cultures from patients with prolactinoma. In monolayer cell cultures from normal rat anterior pituitary, IL-11 and CNTF had no significant effect on the release of either GH or PRL, or on GH mRNA. However, when the cells were cultured in aggregate cultures, in which the three-dimensional structure of the cells is reconstituted, both cytokines, in doses at which they had no effect on monolayer cultures, significantly stimulated both PRL and GH secretion. These data show that IL-11 and CNTF may act as regulatory factors in anterior pituitary cells, in which the three-dimensional structure of the gland is of critical importance.
Search for other papers by B Shan in
Google Scholar
PubMed
Search for other papers by C Schaaf in
Google Scholar
PubMed
Search for other papers by A Schmidt in
Google Scholar
PubMed
Search for other papers by K Lucia in
Google Scholar
PubMed
Search for other papers by M Buchfelder in
Google Scholar
PubMed
Search for other papers by M Losa in
Google Scholar
PubMed
Search for other papers by D Kuhlen in
Google Scholar
PubMed
Search for other papers by J Kreutzer in
Google Scholar
PubMed
Neuroendocrinology Group, Department of Neurosurgery, Department of Neurosurgery, Department of Neurosurgery, Laboratorio de Fisiología y Biología Molecular, IBioBA–CONICET, Max Planck Institute of Psychiatry, Kraepelinstraße 10, D-80804 Munich, Germany
Search for other papers by M J Perone in
Google Scholar
PubMed
Neuroendocrinology Group, Department of Neurosurgery, Department of Neurosurgery, Department of Neurosurgery, Laboratorio de Fisiología y Biología Molecular, IBioBA–CONICET, Max Planck Institute of Psychiatry, Kraepelinstraße 10, D-80804 Munich, Germany
Search for other papers by E Arzt in
Google Scholar
PubMed
Search for other papers by G K Stalla in
Google Scholar
PubMed
Search for other papers by U Renner in
Google Scholar
PubMed
Curcumin (diferuloylmethane), a polyphenolic compound derived from the spice plant Curcuma longa, displays multiple actions on solid tumours including anti-angiogenic effects. Here we have studied in rodent and human pituitary tumour cells the influence of curcumin on the production of hypoxia inducible factor 1α (HIF1A) and vascular endothelial growth factor A (VEGFA), two key components involved in tumour neovascularisation through angiogenesis. Curcumin dose-dependently inhibited basal VEGFA secretion in corticotroph AtT20 mouse and lactosomatotroph GH3 rat pituitary tumour cells as well as in all human pituitary adenoma cell cultures (n=32) studied. Under hypoxia-mimicking conditions (CoCl2 treatment) in AtT20 and GH3 cells as well as in all human pituitary adenoma cell cultures (n=8) studied, curcumin strongly suppressed the induction of mRNA synthesis and protein production of HIF1A, the regulated subunit of the hypoxia-induced transcription factor HIF1. Curcumin also blocked hypoxia-induced mRNA synthesis and secretion of VEGFA in GH3 cells and in all human pituitary adenoma cell cultures investigated (n=18). Thus, curcumin may inhibit pituitary adenoma progression not only through previously demonstrated anti-proliferative and pro-apoptotic actions but also by its suppressive effects on pituitary tumour neovascularisation.